Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/1258
Type
ArticleCopyright
Open access
Collections
- ENSP - Artigos de Periódicos [2411]
- ICICT - Artigos de Periódicos [1406]
- INI - Artigos de Periódicos [3645]
Metadata
Show full item record
DIFFERENTIAL SURVIVAL BENEFIT OF UNIVERSAL HAART ACCESS IN BRAZIL: A NATION-WIDE COMPARISON OF INJECTING DRUG USERS VERSUS MEN WHO HAVE SEX WITH MEN
Author
Affilliation
Oswaldo Cruz Foundation. Sergio Arouca School of Public Health. Social Science Department. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Health Information Department, Center for Scientific and Technological Information. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Sergio Arouca School of Public Health. Department of Epidemiology and Quantitative Methods. Rio de Janeiro, RJ, Brazil.
Brazilian National STD/AIDS Program. Surveillance Unit. Brasilia, DF, Brazil.
Brazilian National STD/AIDS Program. Surveillance Unit. Brasilia, DF, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas Clinical Research Institute. Rio de Janeiro, RJ, Brazil.
University of California. School of Medicine. Department of Family and Preventive Medicine. Division of International Health and Cross Cultural Medicine. San Diego, CA, USA.
Oswaldo Cruz Foundation. Health Information Department, Center for Scientific and Technological Information. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Sergio Arouca School of Public Health. Department of Epidemiology and Quantitative Methods. Rio de Janeiro, RJ, Brazil.
Brazilian National STD/AIDS Program. Surveillance Unit. Brasilia, DF, Brazil.
Brazilian National STD/AIDS Program. Surveillance Unit. Brasilia, DF, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas Clinical Research Institute. Rio de Janeiro, RJ, Brazil.
University of California. School of Medicine. Department of Family and Preventive Medicine. Division of International Health and Cross Cultural Medicine. San Diego, CA, USA.
Abstract
Objective: Brazil accounts for ;70% of injection drug users (IDUs) receiving highly active antiretroviral therapy (HAART) in low-income/middle-income countries. We evaluated the impact of HAART availability/access on AIDS-related mortality among IDUs versus men who have sex with men (MSM).
Design: Nation-wide analysis on Brazilian IDU and MSM diagnosed with AIDS in 2000–2006. Methods: Four national information systems were linked, and Cox regression was used to assess impact of HAART availability/access on differential AIDS-related mortality. Results: Among 28,426 patients, 6777 died during 87,792 personyears of follow-up. Compared with MSM, IDU were significantly less likely to be receiving HAART, to have ever had determinations for CD4 or viral load. After controlling for confounders, IDU had a significantly higher risk of death (adjusted hazard ratio: 1.94; 95% confidence interval: 1.84 to 2.05). Among the subset that had at least 1 CD4 and viral load determination, higher risk of death among IDU persisted (hazard ratio: 1.82; 95% confidence interval: 1.58 to 2.11). Nonwhite ethnicity significantly increased this risk, whereas prompt HAART uptake after AIDS diagnosis reduced the risk of death. After controlling for spatially correlated survival data, AIDS-related mortality remained higher in IDU than in MSM. Conclusions: Despite free/universal HAART access, differential AIDS-related mortality exists in Brazil. Efforts are needed to identify and eliminate these health disparities.
Share